跳至主要内容
临床试验/ACTRN12615001009505
ACTRN12615001009505招募中4 期

In patients having dental extractions, is continuing new oral anticoagulants (NOACs) as safe as continuing warfarin in terms of bleeding amount?

Dr Jennifer Curnow0 个研究点目标入组 400 人开始时间: 2015年9月28日最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Prevention
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Requires simple or surgical dental extraction(s).
  • 2. On therapeutic dose of dabigatran, rivaroxaban, apixaban or warfarin.
  • 3. Able to give informed consent.
  • 4. Age 18 or above.

排除标准

  • 1. Women who are pregnant.
  • 2. Concomitant use of dual anti-platelet therapy.
  • 3. Inherited disorder of haemostasis.
  • 4. Platelet count < 50 x 10^9/L.
  • 5. Procedure for which operator requires OAC interruption.
  • 6. OAC already ceased prior to procedure.
  • 7. Patient on warfarin and INR < 2 or > 4.
  • 8. Severe active oral infection associated with facial swelling.
  • 9. Cockroft-Gaultcreatinine clearance < 25 ml/min for patients on dabigatran, < 30 ml/min for patients on rivaroxaban or apixaban.
  • 11. Surgical extraction of wisdom teeth.

研究者

发起方
Dr Jennifer Curnow

相似试验